Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01307462 · ClinicalTrials.gov registry record · Phase 2
Targeted Therapy of Bronchiolitis Obliterans Syndrome
A Phase 2 study of Bronchiolitis Obliterans, sponsored by Stephanie Lee.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 11
- Study locations
NCT01307462 is a Phase 2 study of Bronchiolitis Obliterans that has completed, run by Stephanie Lee. The registered enrollment target is 36 participants, below the 405-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 11 states.
The verdict
NCT01307462, a Phase 2 study of Bronchiolitis Obliterans, has completed, sponsored by Stephanie Lee.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 11
- Study locations
Study Summary
This phase II trial studies how well giving fluticasone propionate, azithromycin, and montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans who previously underwent stem cell transplant. FAM may be an effective treatment for bronchiolitis obliterans
Conditions Studied
Interventions
- DRUG azithromycin
- DRUG fluticasone propionate
- DRUG montelukast sodium
Study Locations (11)
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
California
- Stanford University - Stanford
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Maryland
- National Cancer Institute Experimental Transplantation & Immunology Branch - Bethesda
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Missouri
- Siteman Cancer Center at Washington University - St Louis
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01307462
The ClinicalTrials.gov registry entry for NCT01307462 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 405-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (91% lower). The listed sponsor is Stephanie Lee, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bronchiolitis Obliterans appearing as the primary indexed condition, and to 3 interventions - of which azithromycin is the first listed.
NCT01307462 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01307462 about?
NCT01307462 is a clinical study titled "Targeted Therapy of Bronchiolitis Obliterans Syndrome". This phase II trial studies how well giving fluticasone propionate, azithromycin, and montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans who previously underwent stem cell transplant. FAM may be an effective treatment for bronchiolitis obliterans
What is the current status of trial NCT01307462?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2011-06. Estimated completion is 2015-12.
What conditions does trial NCT01307462 study?
This clinical trial studies the following conditions: Bronchiolitis Obliterans.
What interventions are being tested in trial NCT01307462?
The interventions under investigation include: azithromycin (DRUG), fluticasone propionate (DRUG), montelukast sodium (DRUG).
Who is sponsoring clinical trial NCT01307462?
This trial is sponsored by Stephanie Lee, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01307462 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiolitis Obliterans
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
RECRUITING
-
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
RECRUITING
-
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
-
Hp129 Xenon Imaging and BOS in Lung Transplantation
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.